test

The Life Sciences Sector’s Wait and See Approach to Dealmaking

This article covers how dealmaking in the life sciences is made up of a wait-and-see approach to dealmaking, amassing so-called firepower for M&A. [Read More]

test

Steve Garbon, The Braff Group Answers the Proust Questionnaire for Dealmakers

This interview features Steve Garbon, Director of Finance at the Braff Group, where he delves into M&A transactions and valuations. [Read More]


test

Virtual Data Rooms Help Kurmann Partners Keep Pharma Clients’ Information Safe

This case study explains how an M&A advisory for pharmaceuticals and medtech uses virtual data rooms for sell-side transactions. [Read More]

test

What exactly is Amazon scheming in the healthcare sphere?

Amazon continues to stay mum on its healthcare ambitions but if you put the pieces together, it’s clear there’s some sort of play in the works. This past year, rumors... [Read More]



test

After Constellation Brands: What’s next for the Canadian Cannabis Sector?

The marijuana industry is worth as much as $35 billion per year. As legal restrictions are eased, will this mean M&A activity?  [Read More]

test

The Braff Group Focuses on Finding the Best Outcome for Healthcare Clients

This case study details how a health care M&A advisory firm uses virtual data rooms to support each stage of the M&A process. [Read More]


test

Filmaceuticals: PE Firms Partner with Pharma to Develop the Next Blockbuster Drug

As recently noted in a Wall Street Journal article, some private equity (PE) firms have begun partnering with pharmaceutical companies, though in a manner far from traditional. [Read More]

test

The Art of the Fail: Lessons from the Trumpcare Debacle

As far as daytime dramas go, the the White House Administration’s ongoing challenges in passing its healthcare bill continue to dominate the news and make for “must-see” TV. After years... [Read More]